354 related articles for article (PubMed ID: 29453492)
1. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Xu R; Ge W; Jiang Q
Eur J Clin Pharmacol; 2018 Jun; 74(6):755-765. PubMed ID: 29453492
[TBL] [Abstract][Full Text] [Related]
2. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
[TBL] [Abstract][Full Text] [Related]
3. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Leow JWH; Ang XJ; Chan ECY
Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
[TBL] [Abstract][Full Text] [Related]
4. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
Cheong EJY; Teo DWX; Chua DXY; Chan ECY
Drug Metab Dispos; 2019 Nov; 47(11):1291-1306. PubMed ID: 31506301
[TBL] [Abstract][Full Text] [Related]
5. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Cheong EJ; Goh JJ; Hong Y; Venkatesan G; Liu Y; Chiu GN; Kojodjojo P; Chan EC
Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
[TBL] [Abstract][Full Text] [Related]
6. Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.
Ismail M; Lee VH; Chow CR; Rubino CM
J Clin Pharmacol; 2018 Apr; 58(4):541-548. PubMed ID: 29239000
[TBL] [Abstract][Full Text] [Related]
7. Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Tse S; Dowty ME; Menon S; Gupta P; Krishnaswami S
J Clin Pharmacol; 2020 Dec; 60(12):1617-1628. PubMed ID: 32592424
[TBL] [Abstract][Full Text] [Related]
8. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
9. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Nakamaru Y; Emoto C; Shimizu M; Yamazaki H
Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults.
Sia JEV; Lai X; Wu X; Zhang F; Li H; Cui C; Liu D
Eur J Pharm Sci; 2023 Mar; 182():106376. PubMed ID: 36626944
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.
Wagner C; Zhao P; Arya V; Mullick C; Struble K; Au S
J Clin Pharmacol; 2017 Oct; 57(10):1295-1304. PubMed ID: 28569994
[TBL] [Abstract][Full Text] [Related]
13. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
Wen HN; He QF; Xiang XQ; Jiao Z; Yu JG
Thromb Res; 2022 Oct; 218():24-34. PubMed ID: 35985100
[TBL] [Abstract][Full Text] [Related]
14. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
15. Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.
Zhao T; Chen Y; Wang D; Wang L; Dong P; Zhao S; Wang C; Meng Q; Sun H; Liu K; Wu J
Cardiovasc Drugs Ther; 2022 Feb; 36(1):121-129. PubMed ID: 33411110
[TBL] [Abstract][Full Text] [Related]
16. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
17. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
18. Application of physiologically-based pharmacokinetic model approach to predict pharmacokinetics and drug-drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine.
Ngo LT; Yang SY; Shin S; Cao DT; Van Nguyen H; Jung S; Lee JY; Lee JH; Yun HY; Chae JW
CPT Pharmacometrics Syst Pharmacol; 2022 Nov; 11(11):1430-1442. PubMed ID: 36193622
[TBL] [Abstract][Full Text] [Related]
19. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.
Wagner C; Pan Y; Hsu V; Grillo JA; Zhang L; Reynolds KS; Sinha V; Zhao P
Clin Pharmacokinet; 2015 Jan; 54(1):117-27. PubMed ID: 25260695
[TBL] [Abstract][Full Text] [Related]
20. Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates.
Umehara KI; Huth F; Won CS; Heimbach T; He H
Biopharm Drug Dispos; 2018 Mar; 39(3):152-163. PubMed ID: 29451681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
